Showing results (101-110 of 114) with videos related to

Sort By:
Pageof 12
Arteriosclerosis, Thrombosis, and Vascular Biology|September 9, 2000
Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosisC W Rittershaus, D P Miller, L J Thomas, et al.
Clinical Pharmacology and Therapeutics|October 23, 2024
First-in-Human Evaluation of Safety, Pharmacokinetics and Muscle Glycogen Lowering of a Novel Glycogen Synthase 1 Inhibitor for the Treatment of Pompe DiseaseJulie C Ullman, Ryan A Dick, Daniela Linzner, et al.
Frontiers in Digital Health|September 17, 2025
Feasibility and acceptability of an in-home digital device health and activity assessment platform in a diverse South Texas cohort: a pilot studyJulia J Mathews, Rachel Mulavelil, Nathaniel Rodrigues, et al.
Bioorganic & Medicinal Chemistry Letters|June 12, 2012
Discovery, oral pharmacokinetics and in vivo efficacy of a highly selective 5-HT4 receptor agonist: clinical compound TD-2749Daniel D Long, Scott R Armstrong, David T Beattie, et al.
Journal of Medicinal Chemistry|August 12, 2009
A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonistsR Murray McKinnell, Scott R Armstrong, David T Beattie, et al.
ACS Medicinal Chemistry Letters|December 21, 2019
Discovery of Axelopran (TD-1211): A Peripherally Restricted μ-Opioid Receptor AntagonistDaniel D Long, Scott R Armstrong, David T Beattie, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentJeffrey A Kaye, Alex B Speers, Amanda B Mar, et al.
Journal of Crohn'S & Colitis|March 13, 2020
Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine ProgrammeWilliam J Sandborn, Deanna D Nguyen, David T Beattie, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Clinical ManifestationsEmily W Paolillo, Amy B Wise, Sreya Dhanam, et al.
Pageof 12